Epic Bio Reports New Data on Hypercompact Cas Proteins Optimized for Broad Therapeutic Applicability
26 oct. 2023 11h09 HE
|
Epic Bio
Epic Bio presented new details on an in-house engineered suite of Cas molecules derived from CasMINI, the smallest Cas known to work in human cells.
Epic Bio to Present at the Upcoming Annual European Society of Gene and Cell Therapy
19 oct. 2023 06h00 HE
|
Epic Bio
SOUTH SAN FRANCISCO, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today...
Epic Bio Announces the Appointment of Weston Miller, M.D., as Chief Medical Officer
17 oct. 2023 06h00 HE
|
Epic Bio
SOUTH SAN FRANCISCO, Calif., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today...
Epic Bio to Present at the Upcoming BMO Life Sciences Private Company Showcase
05 oct. 2023 09h00 HE
|
Epic Bio
SOUTH SAN FRANCISCO, Calif., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today...
Epic Bio to Present Preclinical Data at 28th International Annual Congress of the World Muscle Society
28 sept. 2023 09h00 HE
|
Epic Bio
SOUTH SAN FRANCISCO, Calif., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today...
Epic Bio to Present at Upcoming BMO Biopharma Spotlight Series Event
19 sept. 2023 09h00 HE
|
Epic Bio
SOUTH SAN FRANCISCO, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today...
Epic Bio Reports Discovery of Exceptionally Durable Gene Activators and Creation of Machine Learning Algorithm to Design New Activators
14 sept. 2023 12h00 HE
|
Epic Bio
- Vast high-throughput screening study used to train unique machine learning algorithm to design synthetic activators - - Rational engineering produced activators that induce the most...
Epic Bio Presents Compelling Preclinical Data Supporting Clinical Initiation of EPI-321 for FSHD
16 juin 2023 06h16 HE
|
Epic Bio
- NHP studies demonstrate EPI-321’s favorable safety and pharmacokinetic profile - - IND and CTA applications planned for 2023 - SOUTH SAN FRANCISCO, Calif., June 16, 2023 (GLOBE NEWSWIRE) --...
Epic Bio to Participate in a Fireside Chat at the Stifel Genetic Medicines Day 2023
23 mai 2023 08h00 HE
|
Epic Bio
SOUTH SAN FRANCISCO, Calif., May 23, 2023 (GLOBE NEWSWIRE) -- EPIC BIO, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today...
Epic Bio Presents Preclinical Data on EPI-321 for Facioscapulohumeral Muscular Dystrophy at ASGCT 26th Annual Meeting
19 mai 2023 06h00 HE
|
Epic Bio
- Oral presentation highlights EPI-321 effects on multiple clinically relevant markers - - IND application for EPI-321 planned for 2023 - SOUTH SAN FRANCISCO, Calif., May 19, 2023 (GLOBE...